Back to MW MARSHALL WACE, LLP

PTGXPTGX
Showing 7 of 21 quarters

Position history for MWMARSHALL WACE, LLP's holdings in PROTAGONIST THERAPEUTICS INC

MARSHALL WACE, LLP holds 109,017 shares of PTGX (PROTAGONIST THERAPEUTICS INC), worth $13.4M as of 2026-Q2. The position was decreased (-82.6% shares). PTGX represents 0.0% of MARSHALL WACE, LLP's portfolio.

Current Value

$13.4M

Current Shares

109,017

Total Value Change

-$828,482

Total Shares Change

-206,356

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
109,017
-82.6%
$13.4M0.0%$122.58
0
2026-Q1
Decreased
628,075
-38.7%
$66.2M0.1%$91.30
0
2025-Q4
Decreased
1M
-5.6%
$89.5M0.1%$87.26
0
2025-Q3
New
1.1M
-
$72.1M0.1%$65.14
41
2025-Q1
Exited
0
-100.0%
$00.0%$48.88
0
2024-Q4
Decreased
19,716
-93.8%
$761,0380.0%$38.51
0
2024-Q3
Decreased
315,373
-44.9%
$14.2M0.0%$44.56
0

Other major holders of PTGX: BlackRock, Inc., FARALLON CAPITAL MANAGEMENT, L.L.C.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used